Deciphering the Coagulation Factors in Pulmonary Embolism Incident-Based Thorax Enhanced Chest CT in COVID-19 Patient
Downloads
Introduction: Pulmonary embolism is associated with coagulopathy in COVID-19. It is one of the causes of death in COVID-19 cases and is often underdiagnosed in Indonesia because computed tomography-pulmonary angiography (CTPA) is not used as the gold standard. T
Methods: This study used a prospective analytical design with a cross-sectional approach. The study participants were 45 COVID-19 patients admitted to Santa Elisabeth Hospital, Medan, from January to March 2021. Patients were identified with moderate to severe degrees of COVID-19 and elevated D-dimer and subsequently instructed to undergo a thorax CT scan with IV contrast. The data was analyzed using dependent t-test statistical analysis. The p-value < 0.05 was noted as significant.
Results: Moderate to severe coagulation factor values in COVID-19 patients with mean + SD PT, APTT, D-dimer, fibrinogen, and platelets were 14.11; 30.65; 1172.14; 423.56 and 215.822, respectively. In this study, 22 (48.9%) patients experienced a pulmonary embolism, while the other 23 (51.1%) did not. No significant correlation was found between all coagulation factors and embolism (p > 0.05). The mean + SD well score for pulmonary embolism was 0.23 + 0.57.
Conclusion: Pulmonary embolism was detected in 22 patients (48.49%) with moderate to severe COVID-19 who developed hypercoagulation as indicated by the thorax CT scan with IV contrast. This case was quite common. In resource-constrained situations, a thorax CT scan with IV contrast may replace CTPA in diagnosing/detecting the presence of pulmonary embolism.
Whyte MB, Kelly PA, Gonzalez E, et al. Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res 2020; 195: 95–99.
Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–847.
Coon WW, Willis PW. Deep Venous Thrombosis and Pulmonary Embolism. Am J Cardiol; 11.
Rosyid AN, Yamin M, Puspitasari AD. The Role of Imaging In The Diagnosis of Pulmonary Embolism. Biomol Heal Sci J 2019; 2: 57–62.
Leonard-Lorant I, Delabranche X, Severac F, et al. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D- Dimer Levels. Radiology 2020; 1–9.
Del Nonno F, Colombo D, Nardacci R, et al. Fatal pulmonary arterial thrombosis in a COVID-19 patient, with asymptomatic history, occurred after swab negativization. Thromb J 2021; 19: 1–6.
Lachí¢tre F, Gothot A. Signication clinique du dosage des D-dimères. Rev Med Liege 2007; 62: 29–35.
Masi P, Hékimian G, Lejeune M, et al. Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19-Associated Coagulopathy: Insights From a Prospective, Single-Center Cohort Study. Circulation 2020; 142: 611–614.
Kumar MA, Paulami D, Octavio Franco L, et al. COVID-19 and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV-2 Infection. Ann Oncol 2020; 136: 19–21.
Abou-Ismail MY, Diamond A, Kapoor S, et al. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020; 194: 101.
Bintoro SUY, Dwijayanti NMI, Pramudya D, et al. Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia. F1000Research 2021; 10: 791.
McGonagle D, O'Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020; 2: e437–e445.
Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 2021; 88: 15–27.
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Hear journal Cardiovasc Pharmacother 2020; 6: 260–261.
Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18: 1995–2002.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147.
Poissy J, Goutay J, Caplan M, et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142: 184–186.
Bonaventura A, Vecchié A, Dagna L, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol; 21. Epub ahead of print 2021. DOI: 10.1038/S41577-021-00536-9.
Graziani A, Domenicali M, Zanframundo G, et al. Pulmonary artery thrombosis in COVID-19 patients. Pulmonology 2021; 27: 261.
Mouhat B, Besutti M, Bouiller K, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J; 56. Epub ahead of print 2020. DOI: 10.1183/13993003.01811-2020.
Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J; 56. Epub ahead of print 1 July 2020. DOI: 10.1183/13993003.01365-2020.
Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324: 799–801.
Poor HD. Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest 2021; 160: 1471–1480.
Kichloo A, Dettloff K, Aljadah M, et al. COVID-19 and Hypercoagulability: A Review. Clin Appl Thromb Hemost; 26. Epub ahead of print 2020. DOI: 10.1177/1076029620962853.
Tal S, Spectre G, Kornowski R, et al. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol 2020; 143: 417–424.
Stals MAM, Kaptein FHJ, Kroft LJM, et al. Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients. Postgrad Med 2021; 133: 36–41.
Doherty S. Pulmonary embolism: An update. 47.
Copyright (c) 2023 Wan Betty Pratiwi, Noni Novisari Soeroso, Setia Putra Tarigan, Muntasir Abdullah, Rosita Juwita Sembiring, Aziza Ghanie Icksan, Netty Delvrita Lubis, Putri Chairani Eyanoer
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (